

**FOR IMMEDIATE RELEASE**



## PRIX GALIEN USA

THE GALEN PRIZE

**CONTACT:**

Brandi Horton  
bhorton@vancomm.com  
(202) 331-4323

### **PRIX GALIEN USA ANNOUNCES 2009 FINAL CANDIDATES** *Honorees for Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. 30 gala ceremony*

**NEW YORK (August 7, 2009)** — The 2009 Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that have made a deep impact on the quality of human life at a gala event on September 30. Candidates for the 2009 program provide relief to millions of people living with chronic diseases including cardiovascular disease and diabetes and treatments for people living with cancer and HIV/AIDS. The 2009 Prix Galien USA ceremony will again be emceed by Charlie Rose at the American Museum of Natural History in New York.

Final candidates for the Prix Galien USA 2009 awards are:

**Best Pharmaceutical Agent:**

- AstraZeneca, CRESTOR<sup>®</sup>
- Celgene, Vidaza<sup>®</sup>
- Novartis Oncology, GLEEVEC<sup>®</sup>
- Novartis Pharmaceuticals, EXELON<sup>®</sup> PATCH
- Pfizer, Zyvox<sup>®</sup>
- Schering-Plough, TEMODAR<sup>®</sup> and ZETIA<sup>®</sup>
- Teva Neuroscience, AZILECT<sup>®</sup>
- Wyeth, TORISEL<sup>®</sup>

**Best Biotechnology Product:**

- Amgen, Nplate<sup>®</sup>
- GlaxoSmithKline, PROMACTA<sup>®</sup> and Tykerb<sup>®</sup>

**Best Biotechnology Product (continued):**

- Schering-Plough, PEGINTRON<sup>®</sup>
- Tibotec, INTELENCE<sup>™</sup>
- United Therapeutics, REMODULIN<sup>®</sup>
- Wyeth, Pevnar<sup>®</sup>

**Best Medical Technology:**

- Abbott Vascular, XIENCE<sup>®</sup>
- Boston Scientific, TAXUS<sup>®</sup>
- DCA Design, Lantus<sup>®</sup> SoloSTAR<sup>®</sup>
- GlaxoSmithKline, Veramyst<sup>®</sup> Mistpro<sup>™</sup>
- Veridex, CellSearch<sup>®</sup> CTC Test

**AWARDS COMMITTEE**

**MICHAEL S. BROWN, M.D.\***  
UT Southwestern Medical Center at Dallas

**WALTER GILBERT, M. D.\***  
Harvard University

**JOSEPH GOLDSTEIN, M.D.\***  
UT Southwestern Medical Center at Dallas

**PAUL GREENGARD, PH.D.\***  
Rockefeller University

**ERIC R. KANDEL, M.D.\***  
Columbia University

**RICHARD A. LERNER, M.D.**  
Scripps Research Institute

**PAUL A. MARKS, M.D.**  
Memorial Sloan Kettering Cancer Center

**BENGT SAMUELSSON, M.D. PH.D.\***  
Nobel Foundation, Karolinska Institute

**JAN T. VILCEK, M.D.**  
New York University School of Medicine

**ELIE WIESEL \***  
Honorary Member, Boston University

**GERALD WEISSMANN, M.D.**  
New York University School of Medicine  
Committee Chairman

“Nominees for the Prix Galien USA stand apart from other drugs and technologies in the marketplace for the amount of research and level of skill that was invested in the development of these products that improve lives,” said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of *The FASEB Journal*.

Prix Galien USA honorees are judged on the basis of the innovative nature of the development, application or clinical utility of the drug or technology and whether its discovery can be applied to future biomedical science.

In 2008, the Prix Galien USA committee recognized Selzentry<sup>™</sup> (Pfizer Inc.), Isentress<sup>®</sup> (Merck & Co., Inc.), Soliris<sup>®</sup> (Alexion Pharmaceuticals, Inc.), INFUSE<sup>®</sup> (Wyeth) and Revlimid<sup>®</sup> (The Celgene Corporation).

The Prix Galien USA award is considered the industry’s highest accolade for pharmaceutical research and development — equivalent to the Nobel Prize. The award committee comprises 11 individuals including seven Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals. For details about the Prix Galien USA award and committee visit [www.prix-galien-usa.com](http://www.prix-galien-usa.com).

###

09233134/091423

\* Nobel Laureate